KPTI logo

KPTI
Karyopharm Therapeutics Inc

7,840
Mkt Cap
$177.39M
Volume
495,946.00
52W High
$10.38
52W Low
$3.51
PE Ratio
-0.58
KPTI Fundamentals
Price
$10.00
Prev Close
$9.67
Open
$9.56
50D MA
$7.21
Beta
1.16
Avg. Volume
429,148.00
EPS (Annual)
-$17.93
P/B
-0.60
Rev/Employee
$640,644.74
$250.34
Loading...
Loading...
News
all
press releases
HC Wainwright Brokers Lift Earnings Estimates for KPTI
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report issued...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade
The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·5d ago
News Placeholder
HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)
HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday...
MarketBeat·5d ago
News Placeholder
Promising Nuclear Stocks To Consider - February 16th
Oklo, NuScale Power, Centrus Energy, BWX Technologies, Nano Nuclear Energy, Karyopharm Therapeutics, and Lightbridge are the seven Nuclear stocks to watch today, according to MarketBeat's stock...
MarketBeat·7d ago
News Placeholder
Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Misses Expectations By $3.45 EPS
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its earnings results on Thursday. The company reported ($5.71) EPS for the quarter, missing the consensus estimate of ($2.26) by...
MarketBeat·11d ago
News Placeholder
Karyopharm Therapeutics Q4 Earnings Call Highlights
Karyopharm Therapeutics (NASDAQ:KPTI) executives highlighted upcoming late-stage clinical catalysts, continued revenue growth for its multiple myeloma franchise, and a tighter cost structure during...
MarketBeat·11d ago
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +1.47% and +3.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Analysts
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat...
MarketBeat·11d ago
News Placeholder
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights...
PR Newswire·11d ago
News Placeholder
Uncovering Potential: Karyopharm Therapeutics's Earnings Preview
read more...
Benzinga·12d ago
<
1
2
...
>

Latest KPTI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.